Emerging roles and mechanisms of nanoparticles in cancer treatment: innovations and horizons

On a global scale, cancer ranks high in mortality rate. There is a need for better technology since the current treatments are insufficient. Several new cancer treatments have been developed directly from the lab to the clinic; however, the manufacturing of nanomedicine products, made possible by the rapid expansion of nanotechnology, holds enormous potential for enhancing cancer treatment approaches. The advent of nanotechnology has opened the door to the possibility of multi-functionality and very precise targeting strategies. They have the potential to enhance the pharmacodynamic and pharmacokinetic profiles of conventional treatment approaches, potentially leading to a reevaluation of the effectiveness of current anti-cancer drugs. A novel technique to enhance traditional onco-immunotherapies, recruiting nanoparticle-based delivery systems, which are adaptable carriers for a broad range of molecular payloads. The delivery of molecular payloads to the target site and their release may be well-regulated. We summarize the latest developments in nanobiotechnology for improving immunotherapies and reshaping tumour microenvironments (TMEs) in this review. The current clinical challenges that impede the real-time implementation of cancer nanomedicine are discussed, and this review study consolidates existing knowledge and recent advancements in the use of nanoparticles for cancer therapy. This provides researchers, clinicians, and students with a comprehensive understanding of the current state of the field. Finally, potential future directions are highlighted to enhance the therapeutic efficacy and facilitate the clinical translation of cancer nanomedicine.